Minerva Neurosciences Inc (NAS:NERV)
$ 2.46 -0.02 (-0.81%) Market Cap: 17.20 Mil Enterprise Value: -17.48 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Minerva Neurosciences Inc Roluperidone Update Call Transcript

Apr 13, 2022 / 03:00PM GMT
Release Date Price: $6.05 (+6.84%)
Operator

Hello, and welcome to Minerva Neurosciences Roluperidone Development Update Webcast. Let me introduce Geoff Race, President of Minerva Neurosciences, who will lead today's discussion. Geoff, you may begin.

Geoffrey Robin Race
Minerva Neurosciences, Inc. - President

Thank you, operator, and good morning, everyone. Thanks for joining us today. This morning, we'll provide an update on roluperidone and discuss the minutes from our recent Type C meeting with the FDA. Please note today's call is subject to the disclaimer in the webcast deck available on the Investor and Media section of Minerva's website.

Joining me on the call today is Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. Also joining me today is Dr. Philip Harvey, who is the Leonard M. Miller Professor of Psychiatry and Director of the Division of Psychology at the University of Miami Miller School of Medicine as well as a senior research health scientist at the Department of Veterans Affairs. Both Dr. Luthringer and Dr. Harvey participated in the recent Type C

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot